Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 6Gliosarcoma 6Glioblastoma 6Endometrial Neoplasms 6Carcinoma, Renal Cell 6Sarcoma 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Rhabdomyosarcoma 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Glioma 3Breast Neoplasms 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma 2

Interventions

Cyclophosphamide 24Vincristine 20Carboplatin 18Doxorubicin 15Etoposide 14Melphalan 12Radiotherapy 11Filgrastim 11Cisplatin 11Magnetic Resonance Spectroscopy 10Isotretinoin 10Specimen Handling 9Peripheral Blood Stem Cell Transplantation 9dinutuximab 8Biopsy 8X-Rays 7Topotecan 7Temozolomide 7aldesleukin 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Busulfan 6sargramostim 5Irinotecan 5Vindesine 4Neoadjuvant Therapy 4Ipilimumab 4Ifosfamide 4Dacarbazine 43-Iodobenzylguanidine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroblastoma × temsirolimus × Clear all
NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡